arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Ensysce Biosciences, Inc.

ENSC
$0.34 ▼ -0.03 (-7.87%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ensysce Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.4M
Dividend Yield —
Revenue Growth -15.1% ↗
Op. Margin -221.3% ↗
ROIC 260.4% ↘
FCF / Share $-0.15 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.16M
↓ -15.1% —
Net Income Profit after all expenses
$-2.57M
↓ -48.3% —
Operating Margin Operating profit as % of sales
-221.3%
↑ +40.3% 0th
FCF / Share Free cash flow per share
$-0.15
↑ +70.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Financial Health ↓
3
Cash Quality ↑
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 36 quarters